Compare IMRX & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMRX | OBIO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.3M | 240.7M |
| IPO Year | 2021 | 2020 |
| Metric | IMRX | OBIO |
|---|---|---|
| Price | $4.60 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $17.20 | $14.25 |
| AVG Volume (30 Days) | ★ 2.0M | 221.6K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $2.90 | $2.20 |
| 52 Week High | $10.08 | $5.42 |
| Indicator | IMRX | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 48.95 |
| Support Level | $4.49 | $3.77 |
| Resistance Level | $5.27 | $4.18 |
| Average True Range (ATR) | 0.27 | 0.19 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 81.33 | 47.95 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.